PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

Opdivo Qvantig (nivolumab and hyaluronidase ... It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza ...

The Swiss drugmaker had hoped – despite spartalizumab coming to market well behind other PD-1/PD-L1 checkpoint inhibitors ... and Bristol-Myers Squibb’s Opdivo (nivolumab).

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...

An expert discusses how recent data on adjuvant anti–PD-1 trials highlight the significance of disease-free survival (DFS) ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.